載入中
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
前收盤價
US$0.2799
−US$0.005 · -1.75%
盤中時間採用ET。市場資料可能有所延遲。
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
日內區間
目前US$0.2799
52週區間
目前US$0.2799
盤中時間採用ET。市場資料可能有所延遲。
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
日內區間
目前US$0.2799
52週區間
目前US$0.2799
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 118.6萬 USD | 127.1萬 USD | 134.5萬 USD | 91.1萬 USD | 39.7萬 USD |
| 銷貨成本 | 83.4萬 USD | 65.2萬 USD | 61.2萬 USD | 106.9萬 USD | 20.3萬 USD |
| 毛利 | 35.2萬 USD | 61.9萬 USD | 73.3萬 USD | −15.8萬 USD | 19.4萬 USD |
| 研究與開發 | 519.3萬 USD | 365.5萬 USD | 377.3萬 USD | 346.1萬 USD | 233萬 USD |
| 銷售、一般及管理費用 | 536.2萬 USD | 441萬 USD | 675.8萬 USD | 795.2萬 USD | 1329.2萬 USD |
| 營業費用 | 1055.5萬 USD | 806.5萬 USD | 1053.1萬 USD | 1141.3萬 USD | 1562.2萬 USD |
| 折舊和攤銷 | 5.8萬 USD | 61.8萬 USD | 63.7萬 USD | 65.7萬 USD | 65.1萬 USD |
| 營業利益 | −1020.3萬 USD | −744.6萬 USD | −979.8萬 USD | −1157.1萬 USD | −1542.8萬 USD |
| 淨利 | −654.8萬 USD | −712.1萬 USD | −1300萬 USD | −1150.6萬 USD | −1501.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
